Perspective | Neurogastroenterology and Motility

Transient receptor potential ion channel function in sensory transduction and cellular signaling cascades underlying visceral hypersensitivity

Dafne Balemans,1 Guy E. Boeckxstaens,1 Karel Talavera,2 and Mira M. Wouters1

1Translational Research Center for Gastrointestinal Disorders, University of Leuven, Leuven, Belgium; and 2Laboratory of Ion Channel Research and TRP Research Platform Leuven, Department of Cellular and Molecular Medicine, University of Leuven, Leuven Belgium

Submitted 15 November 2016; accepted in final form 1 April 2017

Balemans D, Boeckxstaens GE, Talavera K, Wouters MM. Transient receptor potential ion channel function in sensory transduction and cellular signaling cascades underlying visceral hypersensitivity. Am J Physiol Gastrointest Liver Physiol 312: G635–G648, 2017. First published April 6, 2017; doi:10.1152/ajpgi.00401.2016.—Visceral hypersensitivity is an important mechanism underlying increased abdominal pain perception in functional gastrointestinal disorders including functional dyspepsia, irritable bowel syndrome, and inflammatory bowel disease in remission. Although the exact pathophysiological mechanisms are poorly understood, recent studies described upregulation and altered functions of nociceptors and their signaling pathways in aberrant visceral nociception, in particular the transient receptor potential (TRP) channel family. A variety of TRP channels are present in the gastrointestinal tract (TRPV1, TRPV3, TRPV4, TRPA1, TRPM2, TRPM5, and TRPM8), and modulation of their function by increased activation or sensitization (decreased activation threshold) or altered expression in visceral afferents have been reported in visceral hypersensitivity. TRP channels directly detect or transduce osmotic, mechanical, thermal, and chemosensory stimuli. In addition, pro-inflammatory mediators released in tissue damage or inflammation can activate receptors of the G protein-coupled receptor superfamily leading to TRP channel sensitization and activation, which amplify pain and neurogenic inflammation. In this review, we highlight the present knowledge on the functional roles of neuronal TRP channels in visceral hypersensitivity and discuss the signaling pathways that underlie TRP channel modulation. We propose that a better understanding of TRP channels and their modulators may facilitate the development of more selective and effective therapies to treat visceral hypersensitivity.

pain; nociceptor; hyperalgesia; sensitization; TRP channels; visceral hypersensitivity; inflammatory mediators; G protein-coupled receptor

Visceral hypersensitivity (VHS) is defined as abnormal abdominal pain perception to intestinal distention and is considered to be the most disturbing and therapy-resistant hallmark of functional gastrointestinal disorders (FGIDs). Over 50% of patients suffering from irritable bowel syndrome (IBS) (64, 113) or functional dyspepsia (FD) (96), two chronic disorders including functional dyspepsia, irritable bowel syndrome, and inflammatory bowel disease in remission report IBS-like symptoms including VHS (86, 87) that cannot be linked with identifiable inflammatory disease activity (45). Even though VHS has undoubtedly a complex and multifactorial etiopathology involving both peripheral and central mechanisms, accumulating evidence shows that the onset of chronic VHS is often preceded by an infectious gastroenteritis or acute inflammatory episode. It is currently hypothesized that a subgroup of these patients fail to resolve this initial inflammation, leading to persistent immune activation, in particular, mast cell activation and the subsequent release of pro-inflammatory mediators that activate or sensitize visceral nociceptors (14, 129). This finding is further underscored by the fact that supernatant of IBS intestinal biopsies contain more mast cell mediators such as tryptase, serotonin, and histamine that can activate (22) or sensitize (128) human enteric neurons, leading to aberrant pain perception. So far, numerous mediators have been shown to directly activate gut afferents by binding to various cell surface receptors and channels expressed on their peripheral endings (20). In particular, transient receptor potential (TRP) cation channels seem to play a key role in visceral nociception, as they can be directly activated or act as secondary transducers of various G protein-coupled receptors (GPCRs) that are activated by pro-inflammatory mediators. In this review, we highlight the present knowledge on the functional roles of TRPV1, TRPA1, TRPV4, TRPM2, and TRPM8 in VHS. We discuss the signaling pathways that contribute to TRP sensitization and propose potential novel therapeutic strategies to treat VHS.

TRP Channels in the Viscera

Visceral (nociceptive) stimuli are sensed by a specialized set of neurons with their cell body in the dorsal root ganglion and free sensory nerve endings in the intestinal wall. These nerve terminals reside in a complex signaling environment where they are subjected to mechanical distorsion during distension and a changing milieu of neuroactive signaling molecules that can be modulated by stress, immune cells, and the microbiome (20). The peripheral nerve endings in the gut are equipped with numerous receptors and ion channels that allow them to detect and respond to diverse chemical, mechanical, and thermal stimuli. These visceral signals are then transduced to interneurons in the dorsal horn of the spinal cord that transmit the signal to the brainstem and, if intensely enough, to the cortex for conscious perception. The best studied set of molecular sensors are the TRP...
channels, as they can bind many endogenous lipids and exogenous natural or synthetic compounds (17).

Somatic pain studies repeatedly show that direct activation of TRP channels in sensory nerves triggers protective mechanisms that lead to withdrawal from danger (pain), removal of irritants (itch and cough), and resolution of infection (neurogenic inflammation) (114). These physiologic processes are essential for survival, and are normally under tight control and cease when the initial trigger, for example, inflammation, is removed. However, in the diseased state, longer lasting and sometimes even persistent neuronal hypersensitivity is maintained by TRP channel sensitization (49, 114). This process is characterized by aberrant pain responses to noxious and non-noxious stimuli, and is a major cause of chronic disorders such as asthma, psoriasis, and FGIDs. The exact mechanisms involved are not fully understood, but it seems that TRP channels act as targets for major downstream effectors of GPCR signaling. Stimulation of GPCR signaling by inflammatory mediators enhances the response to TRP agonists via sensitization, making them very attractive therapeutic targets in various disorders that are characterized by neuronal hypersensitivity.

To date there are 28 TRP genes described in mammals that are grouped into six TRP channel subfamilies: TRPC (canonical), TRPM (melastatin), TRPV (vanilloid), TRPA (ankyrin), TRPML (mucolipin), and TRPP (or PKD, polycystin) (130). TRP channels nonselectively conduct cations and, when activated, lead to increased intracellular Na⁺ and Ca²⁺ concentrations, the initiation of neuronal excitation, and a plethora of cellular responses that are relevant to chemo-, thermo-, and/or mechanosensation.

In the gastrointestinal tract, multiple cells express a variety of TRP channels (TRPV1, TRPV3, TRPA1, TRPM2, TRPM5, and TRPM8) that are crucial in tasting seasoned food, thermoregulation of the gut, peristalsis, secretion, mucosal homeostasis, tissue protection, epithelial restitution, controlling of the membrane potential and excitability of neurons, epithelial cells, muscle cells and interstitial cells of Cajal, and visceral sensation (49). Emerging clinical evidence demonstrates aberrant TRP channel expression or function in FGIDs (4, 5, 128), while preclinical models using TRP agonists and transgenic mouse models lacking TRP channels confirm the crucial role of TRP channels in the development and maintenance of colonic afferent hypersensitivity (27, 31, 49, 112). In the following paragraphs, we present an overview of the function and mediators involved in sensitization of TRPV1, TRPV4, TRPA1, TRPM2, and TRPM8 channels in the pathophysiology of VHS as seen in FGIDs.

**TRPV1.** The best characterized and most studied nociceceptor in VHS is TRPV1. TRPV1 is a voltage-gated outwardly rectifying cation channel activated by noxious heat, acidosis (pH < 6) (110), exogenous irritants such as capsaicin (the active component of hot peppers) (25), allyl isothiocyanate (AITC, i.e., mustard oil) (34), and a variety of endogenous lipid compounds, including anandamide (140) and some lipoxigenase metabolites of arachidonic acid (53).

In the gastrointestinal tract, TRPV1 is highly expressed by extrinsic sensory neurons and by intrinsic enteric neurons (7, 8, 121). An overview of clinical and preclinical studies providing evidence for the role of TRPV1 in VHS is presented in Table 1. For example, Akbar et al. (4, 5) showed that, in comparison with healthy individuals, quiescent inflammatory bowel disease (IBD) patients with IBS-like symptoms (4) and IBS patients (5) showed increased numbers of TRPV1-positive nerve fibers that correlate with abdominal pain scores. Others provided rather functional evidence for TRPV1 deregulation, as ingestion of capsaicin capsules caused increased pain responses in patients with diarrhea-predominant IBS and FD patients compared with healthy individuals (41, 46, 68). These findings were corroborated by our group; visceral hypersensitive IBS patients, identified by colorectal balloon distention, experienced more pain during rectal application of capsaicin compared with normosensitive patients and healthy individuals (113). Even though hypersensitive patients reported more pain to rectal capsaicin application, rectal TRPV1 mRNA and protein expression was similar between IBS patients and healthy individuals, suggesting that TRPV1 is sensitized rather than upregulated (113). In a follow-up study, TRPV1 responses to capsaicin were indeed potentiated in rectal submucosal neurons of IBS patients but not in healthy subjects (128). Additionally, murine primary sensory DRG neurons revealed an increased capsaicin-induced intracellular Ca²⁺ response after overnight incubation with rectal biopsy supernatants of IBS patients but not of healthy subjects, indicating that submucosal biopsies of IBS patients release mediators that can sensitize TRPV1 (128).

The involvement of TRPV1 in VHS has also been demonstrated in various preclinical models of visceral hypersensitivity. For example, increased TRPV1 immunoreactivity was detected in mouse DRG neurons of a post-2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis model and was linked to chemical (capsaicin) and mechanical (colonic distention) VHS (78). Moreover, mice deficient in TRPV1 failed to develop postinflammatory VHS following acute colitis induced by dextran sulfate sodium (DSS) (66). Finally, in a rat stress model of maternal separation, visceral hypersensitivity in adult rats was reversed by a TRPV1 antagonist (112), further underscoring the role of TRPV1 in VHS.

**TRPV4.** The fourth member of the vanilloid subfamily of TRP channels, TRPV4, is a Ca²⁺-permeable cation channel that has been detected in both sensory and nonsensory cells. In the gastrointestinal tract, TRPV4 has been reported to be primarily expressed on extrinsic afferent nerve fibers and a variety of nonneuronal cells such as epithelial and endothelial cells. Although TRPV4 was originally identified as a channel activated by hypo-osmotic swelling (69, 105, 127), recent evidence indicates that the channel can be activated by diverse stimuli, including shear stress (38), noxious warm temperatures (44, 124), acidity (108), phorbol esters (both protein kinase C-activating and nonactivating phorbol esters) (38, 122, 131), and downstream metabolites of arachidonic acid (epoxyeicosatrienoic acids) (29, 119, 123).

Accumulating evidence indicates that TRPV4 activation triggers VHS (overview in Table 2). For example, Cenac et al. (29) elegantly demonstrated that the levels of the TRPV4 agonist 5,6-EET, but not of TRPV1 or TRPA1 agonists, were increased in IBS biopsies compared with controls, and that these increased levels correlated with abdominal pain and bloating scores. Intracolonic infusion of supernatants from IBS biopsies, but not from controls, induced VHS in mice, while knockdown of TRPV4 in mouse primary afferent neurons by siRNA inhibited the hypersensitivity caused by supernatants from IBS biopsies (29). Moreover, polyunsaturated fatty acid...
Table 1. Implications of TRPV1 in the pathophysiology of visceral hypersensitivity in FGIDs

<table>
<thead>
<tr>
<th>Tissue (Disease)</th>
<th>Species</th>
<th>Tissue or Cell Type</th>
<th>Technique</th>
<th>Result</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colon (IBD)</td>
<td>Human</td>
<td>Rectosigmoid biopsies</td>
<td>Immunohistochemistry</td>
<td>Increased TRPV1 nerve fibers</td>
<td>4</td>
</tr>
<tr>
<td>Colon (IBS)</td>
<td>Human</td>
<td>Rectosigmoid biopsies</td>
<td>Immunohistochemistry and symptom questionnaires</td>
<td>Increased TRPV1 nerve fibers correlating with abdominal pain</td>
<td>5</td>
</tr>
<tr>
<td>Colon (IBS)</td>
<td>Human</td>
<td>Rectal biopsies</td>
<td>Immunohistochemistry, RT-qPCR</td>
<td>No upregulation of TRPV1</td>
<td>113</td>
</tr>
<tr>
<td>Colon (DSS colitis)</td>
<td>Mice</td>
<td>HEK-293 cells and dorsal root ganglia</td>
<td>Immunohistochemistry, RT-qPCR, Western blot</td>
<td>Upregulation TRPV1 by substance P</td>
<td>66</td>
</tr>
<tr>
<td>Colon (TNBS colitis)</td>
<td>Rats</td>
<td>Dorsal root ganglia</td>
<td>Immunohistochemistry</td>
<td>Increased TRPV1 immunoreactivity</td>
<td>78</td>
</tr>
</tbody>
</table>

| Colon (IBS-D)    | Human   | Symptom questionnaires | Increased pain sensation to capsaicin capsules | | 41        |
| Stomach and small intestine (FD) | Human | Symptom questionnaires | Increased pain sensation to capsaicin capsules | | 46, 68    |
| Colon (IBS)      | Human   | Symptom questionnaires | Rectal capsaicin application induced increased pain perception. | | 113       |
| Rectum and colon (IBS) | Human and mice | Submucosal neurons (human) and dorsal root ganglia (mouse) | Calcium imaging and symptom questionnaires | Increased TRPV1 sensitivity in IBS mediated by histamine and Hrh1. Symptom reduction after treatment with Hrh1 antagonist TRPV1 deficiency prevents postinflammatory VHS | 128       |
| Colon (DSS colitis) | Mice | Serosal afferent nerves | Colorectal distention and afferent nerve recording | Inflammatory mediators sensitize TRPV1 resulting in VHS, an effect lacking in TRPV1 knockout mice | 56        |
| Colon (DSS colitis) | Mice | Dorsal root ganglia | Patch-clamp | TRPV1 sensitization by 5-HT | 106       |
| Colon (DSS colitis) | Rat | Dorsal root ganglia | Maternal separation: colorectal distention reversed by TRPV1 antagonist Depletion 5-HT decreases capsaicin response and VHS | VHS after maternal separation reversed by TRPV1 antagonist | 112       |

**Expression profiles**

- **Colon (IBD)**: Human Rectosigmoid biopsies
- **Colon (IBS)**: Human Rectosigmoid biopsies
- **Colon (IBS)**: Human Rectal biopsies
- **Colon (DSS colitis)**: Mice HEK-293 cells and dorsal root ganglia
- **Colon (TNBS colitis)**: Rats Dorsal root ganglia

**Functional data**

- **Colon (IBS-D)**: Human Symptom questionnaires
- **Stomach and small intestine (FD)**: Human Symptom questionnaires
- **Colon (IBS)**: Human Symptom questionnaires
- **Rectum and colon (IBS)**: Human and mice Submucosal neurons (human) and dorsal root ganglia (mouse)
- **Colon (DSS colitis)**: Mice Colorectal distention
- **Colon (DSS colitis)**: Mice Serosal afferent nerves
- **Colon (DSS colitis)**: Mice Dorsal root ganglia
- **Colon**: Rat Dorsal root ganglia

**Expression profiles**

- **Colon (IBD)**: Increased TRPV1 nerve fibers
- **Colon (IBS)**: Increased TRPV1 nerve fibers correlating with abdominal pain
- **Colon (IBS)**: No upregulation of TRPV1
- **Colon (DSS colitis)**: Upregulation TRPV1 by substance P
- **Colon (TNBS colitis)**: Increased TRPV1 immunoreactivity

**Increased Ca2+ responses to TRPV4 agonist GSK1016790A in colon**

In addition to the clinical data indicating a potential role for TRPV4 in VHS, various preclinical models already provide functional evidence. Activation of TRPV4 by the TRPV4 agonist 4α-phorbol 12,13-didecanoate (4α-PDD) in colonic projections of DRG neurons induced mechanical VHS in a dose-dependent manner (27). Moreover, mechanosensory responses of colonic serosal and mesenteric fibers were enhanced by the TRPV4 agonist 5,6-EET, and significantly reduced by targeted deletion of TRPV4 or by the TRPV4 antagonist ruthenium red (21). Others showed that intervertebral pretreatment of mice with TRPV4 directed small interfering RNA (siRNA) reduced basal visceral nociception, as well as 4α-PDD agonist-induced hypersensitivity (27). Furthermore, selective blockade of TRPV4 in the TNBS colitis mouse model alleviated colitis and pain associated with acute intestinal inflammation (36). On the basis of these data, TRPV4 seems an important colonic nociceptor that mediates both mechanical and chemical hyperalgesia. Despite these findings, more clinical studies investigating the role of TRPV4 in VHS in IBS, FD, and IBD patients in remission are warranted.

**TRPA1**

In mammals, TRPA1 is the sole member of the TRPA gene subfamily. TRPA1 is a cold- and mechanosensitive TRP channel activated by cooling to the noxious cold range of temperatures (17°C) (104). TRPA1 is best known as a sensor of bacterial lipopolysaccharides (77, 15), menthol (59), inflammatory fatty acids, prostaglandin metabolites, and hydrogen peroxide (9, 72). In addition, TRPA1 acts as a sensor of bacterial lipopolysaccharides (77, 46, 68).
In the gastrointestinal tract of mammals, TRPA1 has been shown to be expressed on extrinsic primary afferent nerves as well as in intrinsic enteric neurons (84, 104). Besides neuronal cells, TRPA1 is also highly expressed in nonneuronal 5-hydroxytryptamine-releasing enterochromaffin cells (80), cholecystokinin-releasing endocrine cells (91), and intestinal epithelial cells (63).

Recent reports identified TRPA1 as a target for the noxious and inflammatory irritant AITC in peripheral sensory neurons, implicating a functional role in pain and neurogenic inflammation (overview in Table 3). Although the majority of the literature on TRPA1 in VHS is based on preclinical studies, a recent study reported upregulation of TRPA1 mRNA expression in biopsies of active IBD patients but not in quiescent IBD patients (65). This effect on acute pain perception was already described by Meseguer et al. (77) who found that TRPA1 channels mediate acute neurogenic inflammation and pain produced by LPS. Also, in mice, intracolonic administration of a TRPA1 agonist increased the visceromotor response, an effect that was absent in TRPA1 deficient mice (19, 26). Others showed upregulation of TRPA1 expression in colonic DRGs of mice suffering from acute TNBS-induced colitis that led to an enhanced visceromotor response to colorectal distention, an effect that was prevented by intrathecal pretreatment with a TRPA1 antisense oligodeoxynucleotide (134) and TRPA1 blockade (115). In addition, the TRPA1 agonist AITC induced colonic hypersensitivity in a mild DSS colitis model that was prevented by treatment with a TRPA1 antagonist (79).

Besides its role in acute pain perception, preclinical models showed that intracolonic treatment of newborn mouse pups with the TRPA1 agonist AITC triggers a permanent increase in the percentage of TRPA1-positive DRG neurons as well as in intrinsic enteric neurons. Besides neuronal cells, TRPA1 is also highly expressed in nonneuronal 5-hydroxytryptamine-releasing enterochromaffin cells (80), cholecystokinin-releasing endocrine cells (91), and intestinal epithelial cells (63).

Recent reports identified TRPA1 as a target for the noxious and inflammatory irritant AITC in peripheral sensory neurons, implicating a functional role in pain and neurogenic inflammation (overview in Table 3). Although the majority of the literature on TRPA1 in VHS is based on preclinical studies, a recent study reported upregulation of TRPA1 mRNA expression in biopsies of active IBD patients but not in quiescent IBD patients (65). This effect on acute pain perception was already described by Meseguer et al. (77) who found that TRPA1 channels mediate acute neurogenic inflammation and pain produced by LPS. Also, in mice, intracolonic administration of a TRPA1 agonist increased the visceromotor response, an effect that was absent in TRPA1 deficient mice (19, 26). Others showed upregulation of TRPA1 expression in colonic DRGs of mice suffering from acute TNBS-induced colitis that led to an enhanced visceromotor response to colorectal distention, an effect that was prevented by intrathecal pretreatment with a TRPA1 antisense oligodeoxynucleotide (134) and TRPA1 blockade (115). In addition, the TRPA1 agonist AITC induced colonic hypersensitivity in a mild DSS colitis model that was prevented by treatment with a TRPA1 antagonist (79).

Besides its role in acute pain perception, preclinical models showed that intracolonic treatment of newborn mouse pups with the TRPA1 agonist AITC triggers a permanent increase in the percentage of TRPA1-positive DRG neurons as well as in intrinsic enteric neurons. Besides neuronal cells, TRPA1 is also highly expressed in nonneuronal 5-hydroxytryptamine-releasing enterochromaffin cells (80), cholecystokinin-releasing endocrine cells (91), and intestinal epithelial cells (63).

Recent reports identified TRPA1 as a target for the noxious and inflammatory irritant AITC in peripheral sensory neurons, implicating a functional role in pain and neurogenic inflammation (overview in Table 3). Although the majority of the literature on TRPA1 in VHS is based on preclinical studies, a recent study reported upregulation of TRPA1 mRNA expression in biopsies of active IBD patients but not in quiescent IBD patients (65). This effect on acute pain perception was already described by Meseguer et al. (77) who found that TRPA1 channels mediate acute neurogenic inflammation and pain produced by LPS. Also, in mice, intracolonic administration of a TRPA1 agonist increased the visceromotor response, an effect that was absent in TRPA1 deficient mice (19, 26). Others showed upregulation of TRPA1 expression in colonic DRGs of mice suffering from acute TNBS-induced colitis that led to an enhanced visceromotor response to colorectal distention, an effect that was prevented by intrathecal pretreatment with a TRPA1 antisense oligodeoxynucleotide (134) and TRPA1 blockade (115). In addition, the TRPA1 agonist AITC induced colonic hypersensitivity in a mild DSS colitis model that was prevented by treatment with a TRPA1 antagonist (79).

Besides its role in acute pain perception, preclinical models showed that intracolonic treatment of newborn mouse pups with the TRPA1 agonist AITC triggers a permanent increase in the percentage of TRPA1-positive DRG neurons as well as in intrinsic enteric neurons. Besides neuronal cells, TRPA1 is also highly expressed in nonneuronal 5-hydroxytryptamine-releasing enterochromaffin cells (80), cholecystokinin-releasing endocrine cells (91), and intestinal epithelial cells (63).

Recent reports identified TRPA1 as a target for the noxious and inflammatory irritant AITC in peripheral sensory neurons, implicating a functional role in pain and neurogenic inflammation (overview in Table 3). Although the majority of the literature on TRPA1 in VHS is based on preclinical studies, a recent study reported upregulation of TRPA1 mRNA expression in biopsies of active IBD patients but not in quiescent IBD patients (65). This effect on acute pain perception was already described by Meseguer et al. (77) who found that TRPA1 channels mediate acute neurogenic inflammation and pain produced by LPS. Also, in mice, intracolonic administration of a TRPA1 agonist increased the visceromotor response, an effect that was absent in TRPA1 deficient mice (19, 26). Others showed upregulation of TRPA1 expression in colonic DRGs of mice suffering from acute TNBS-induced colitis that led to an enhanced visceromotor response to colorectal distention, an effect that was prevented by intrathecal pretreatment with a TRPA1 antisense oligodeoxynucleotide (134) and TRPA1 blockade (115). In addition, the TRPA1 agonist AITC induced colonic hypersensitivity in a mild DSS colitis model that was prevented by treatment with a TRPA1 antagonist (79).

### Table 2. Implications of TRPV4 in the pathophysiology of visceral hypersensitivity in FGIDs

<table>
<thead>
<tr>
<th>Tissue (disease)</th>
<th>Species</th>
<th>Tissue or cell type</th>
<th>Expression profiles</th>
<th>Technique</th>
<th>Result</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colon (IBD)</td>
<td>Human</td>
<td>Surgical resections and colonic biopsies</td>
<td>Immunohistochemistry and RT-qPCR</td>
<td></td>
<td>Upregulation TRPV4 in sensory neurons, serosal blood vessels and colonic biopsies</td>
<td>21, 36</td>
</tr>
<tr>
<td>Ilium, colon, and rectum</td>
<td>Human</td>
<td>Serosal afferent nerves</td>
<td>Afferent nerve recording</td>
<td></td>
<td></td>
<td>74</td>
</tr>
<tr>
<td>Rectum and colon (IBS)</td>
<td>Human and mice</td>
<td>Submucosal neurons (human) and dorsal root ganglia (mice)</td>
<td>Calcium imaging</td>
<td></td>
<td>Increased TRPV4 sensitivity in IBS mediated by histamine and Hrh1.</td>
<td>11</td>
</tr>
<tr>
<td>Colon (TNBS colitis)</td>
<td>Mice</td>
<td>Colonic biopsies (human) and dorsal root ganglia (mice)</td>
<td>Calcium imaging</td>
<td></td>
<td>Knockdown of TRPV4 inhibited hypersensitivity caused by supernatants from IBS biopsies</td>
<td>29</td>
</tr>
<tr>
<td>Colon</td>
<td>Mice</td>
<td>Evaluation of pain-related behavior</td>
<td>Colorectal distention</td>
<td></td>
<td>TRPV4 antagonists alleviates colitis and inflammatory pain</td>
<td>36</td>
</tr>
<tr>
<td>Colon</td>
<td>Mice</td>
<td>Serosal and mesenteric afferent nerves</td>
<td>Colorectal distention and afferent nerve recording</td>
<td></td>
<td>TRPV4 knockout mice or treatment with TRPV4 siRNA decreases visceromotor response. Serosal and mesenteric afferent nerves response to TRPV4 agonist 5,6-EET</td>
<td>21</td>
</tr>
<tr>
<td>Colon</td>
<td>Mice</td>
<td>Dorsal root ganglia</td>
<td>Colorectal distention and calcium imaging</td>
<td></td>
<td>Intracolonic administration of histamine and serotonin potentiated TRPV4-induced VHS, absent mice treated with TRPV4 siRNA. Histamine and serotonin potentiate the TRPV4 response on mouse dorsal root ganglia</td>
<td>28</td>
</tr>
<tr>
<td>Colon</td>
<td>Mice</td>
<td>Dorsal root ganglia</td>
<td>Colorectal distention and calcium imaging</td>
<td></td>
<td>Intracolonic administration of PAR-2 agonists induces VHS, absent mice treated with TRPV4 siRNA. PAR-2 agonists potentiate the TRPV4 response in mouse dorsal root ganglia</td>
<td>27, 100</td>
</tr>
<tr>
<td>Colon</td>
<td>Mice</td>
<td>Dorsal root ganglia</td>
<td>Colorectal distention and calcium imaging</td>
<td></td>
<td>Intracolonic PAR-4 agonist inhibits PAR-2 agonist and TRPV4 agonist-induced VHS. PAR-4 agonist inhibited calcium response to PAR-2 and TRPV4 agonist in mouse dorsal root ganglia</td>
<td>10</td>
</tr>
</tbody>
</table>

PAR, proteinase-activated receptor; 5,6-EET, 5,6-epoxyeicosatrienoic acid.
TRPV1 in VHS. Indeed, in sensory neurons, TRPA1 has been shown to act in concert with TRPV1 (see details below). Finally, we recently demonstrated an increased TRPA1 agonist-induced Ca<sup>2+</sup> response in rectal submucosal neurons of IBS patients compared with those of healthy controls (11). Furthermore histamine was able to potentiate TRPA1 responses in submucosal neurons of healthy subjects. Again, TRPA1 mRNA expression was not upregulated in rectal biopsies of IBS patients compared with healthy individuals, suggesting that also TRPA1 is sensitized in IBS (11). Even though these studies are promising, more clinical studies are required to better understand the role of TRPA1 in VHS in FGIDs.

TRPM2. TRPM2 is a heat-sensitive TRP channel that belongs to the melastatin subgroup of the TRP channel superfamily. It can be activated by intracellular ADP ribose and extracellular stimuli such as reactive oxygen species (47, 85, 125). TRPM2 channels are expressed by intrinsic and spinal primary afferent neurons innervating the distal colon in rat (73). Besides neuronal cells, TRPM2 is also expressed in mucosal macrophages and mast cells and contributes to the progression of experimental colitis and food allergy in mice (81, 133).

Several reports show that TRPM2 deficiency has anti-alldynic effects in a wide variety of inflammatory and neuropathic pain mouse models (101), suggesting that TRPM2 may be a new therapeutic target for controlling chronic pain. Furthermore, a recent study found evidence for a role of TRPM2 in visceral nociception and hypersensitivity (73) (overview in Table 4). TRPM2 expression was increased in distal colon of a TNBS colitis rat model, and oral administration of TRPM2 antagonist or TRPM2 deficiency reduced the visceromotor response to noxious colorectal distention in rats. These data suggest that TRPM2 is involved in VHS and may present a novel therapeutic target for VHS triggered by intestinal inflammation. To date clinical studies investigating the role of TRPM2 in visceral pain sensation in FGIDs are completely lacking, but are definitely warranted to establish preclinical evidence.

Table 3. Implications of TRPA1 in the pathophysiology of visceral hypersensitivity in FGIDs

<table>
<thead>
<tr>
<th>Tissue (disease)</th>
<th>Species</th>
<th>Tissue or Cell Type</th>
<th>Technique</th>
<th>Result</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colon (IBD)</td>
<td>Human</td>
<td>Colonic biopsies</td>
<td>Immunohistochemistry and RT-qPCR</td>
<td>Upregulation TRPA1</td>
<td>65</td>
</tr>
<tr>
<td>Colon (mustard oil colitis)</td>
<td>Mice</td>
<td>Colonic tissue</td>
<td>RT-qPCR</td>
<td>Upregulation TRPA1 on colonic afferent nerves</td>
<td>61</td>
</tr>
<tr>
<td>Colon (TNBS)</td>
<td>Mice</td>
<td>Dorsal root ganglia</td>
<td>Immunohistochemistry</td>
<td>Treatment mice pups with TRPA1 agonist increases TRPA1 expression</td>
<td>31</td>
</tr>
<tr>
<td>Colon</td>
<td>Mice</td>
<td>Dorsal root ganglia</td>
<td>Western blot</td>
<td>Upregulation TRPA1</td>
<td>115, 134</td>
</tr>
<tr>
<td>Rectum and colon (IBS)</td>
<td>Human and mice</td>
<td>Submucosal neurons (human) and dorsal root ganglia (mice)</td>
<td>Calcium imaging</td>
<td>Increased TRPA1 sensitivity in IBS mediated by histamine and Hrh1.</td>
<td>11</td>
</tr>
<tr>
<td>Colon</td>
<td>Mice</td>
<td>Colorectal distention</td>
<td>Colorectal distention</td>
<td>Intracolonic administration of TRPA1 agonists induces VHS, absent in TRPA1 knockout mice</td>
<td>19, 26</td>
</tr>
<tr>
<td>Colon</td>
<td>Mice</td>
<td>Colorectal distention</td>
<td>Colorectal distention</td>
<td>Treatment mice pups with TRPA1 agonist results in adult VHS</td>
<td>31</td>
</tr>
<tr>
<td>Colon</td>
<td>Mice</td>
<td>Colorectal distention</td>
<td>Colorectal distention</td>
<td>Intracolonic PAR-2 agonist administration induces VHS, absent in TRPA1 knockout mice</td>
<td>26</td>
</tr>
<tr>
<td>Colon</td>
<td>Mice</td>
<td>Serosal and mesenteric afferent nerves</td>
<td>Colorectal distention and afferent nerve recording</td>
<td>Bradykinin increases mechanosensitivity in afferent nerves and VHS, absent in TRPA1 knockout mice</td>
<td>19</td>
</tr>
<tr>
<td>Colon</td>
<td>Mice</td>
<td>Serosal and mesenteric afferent nerves</td>
<td>Afferent nerve recording</td>
<td>No interaction of PAR-2 and TRPM2 in splanchnic afferents</td>
<td>19</td>
</tr>
<tr>
<td>Colon (TNBS and DSS colitis)</td>
<td>Rats and mice</td>
<td>Serosal and mesenteric afferent nerves</td>
<td>Colorectal distention</td>
<td>VHS absent in TRPA1 knockout mice and by TRPM2 blockade</td>
<td>26, 79, 115, 134</td>
</tr>
</tbody>
</table>

TRPA, transient receptor potential (ankyrin).

TRPM2. TRPM2 is a heat-sensitive TRP channel that belongs to the melastatin subgroup of the TRP channel superfamily. It can be activated by intracellular ADP ribose and extracellular stimuli such as reactive oxygen species (47, 85, 125). TRPM2 channels are expressed by intrinsic and spinal primary afferent neurons innervating the distal colon in rat (73). Besides neuronal cells, TRPM2 is also expressed in mucosal macrophages and mast cells and contributes to the progression of experimental colitis and food allergy in mice (81, 133).

Several reports show that TRPM2 deficiency has anti-alldynic effects in a wide variety of inflammatory and neuropathic pain mouse models (101), suggesting that TRPM2 may be a new therapeutic target for controlling chronic pain. Furthermore, a recent study found evidence for a role of TRPM2 in visceral nociception and hypersensitivity (73) (overview in Table 4). TRPM2 expression was increased in distal colon of a TNBS colitis rat model, and oral administration of TRPM2 antagonist or TRPM2 deficiency reduced the visceromotor response to noxious colorectal distention in rats. These data suggest that TRPM2 is involved in VHS and may present a novel therapeutic target for VHS triggered by intestinal inflammation. To date clinical studies investigating the role of TRPM2 in visceral pain sensation in FGIDs are completely lacking, but are definitely warranted to establish preclinical evidence.

TRPM8. The cold and menthol receptor TRPM8 is activated by cooling, menthol, and cooling compounds such as spear-
mechanisms contributing to persistent TRP channel activation or sensitization is key for the development of novel therapeutic strategies. In general, TRP channels play three distinct cellular roles: 1) TRP channels operate as molecular sensors, that is, primary detectors and transducers of chemical and physical stimuli from the microenvironment; 2) TRP channels act as downstream or secondary transducers of cell activation mediated by GPCRs or ion channel activation; and 3) TRP channels function as ion transport channels, for example, for Ca$^{2+}$ and Mg$^{2+}$ responsible for cellular homeostasis. Within primary afferent neurons, translation of signals detected by TRP channels into effector responses is carried out by the local release of neuropeptides from the peripheral fibers of TRP-expressing afferent neurons, which causes changes in local tissue function, and on the other hand, by transmission of the signals to the central nervous system resulting in (nociceptive) sensation.

Long-term deregulation and disease can lead to chronic TRP channel sensitization, thereby triggering VHS. However, the exact mechanisms underlying long-term sensitization of TRP channels in FGIDs are not fully understood. From somatic pain studies and studies in the skin we know that the GPCR-TRP axis plays a central role in TRP sensitization (114). Indeed, GPCRs enable sensory neurons to detect diverse stimulants and inhibitors, including amines (histamine and serotonin), peptides (kinins, tachykinins, and opioids), purines and nucleotides (adenosine and ATP), lipids (prostaglandins), steroids (bile acids), and proteases (serine and cysteine). The capacity of GPCRs to excite primary sensory neurons requires activation of TRP channels, and the activities of many GPCRs converge on a small number of TRP channels that are vitally important for sensory signaling. GPCRs can stimulate TRPs by two general mechanisms: 1) G$\alpha$-mediated activation of phospholipases that relieve phosphatidylinositol 4,5-bisphosphate (PIP2)-dependent channel inhibition and generate endogenous TRP agonists and 2) stimulation of kinases (protein kinase C, PKA, and tyrosine kinases) that phosphorylate TRPs to in-

Table 5. Implications of TRPM8 in the pathophysiology of visceral hypersensitivity in FGIDs

<table>
<thead>
<tr>
<th>Tissue (Disease)</th>
<th>Species</th>
<th>Tissue or Cell Type</th>
<th>Technique</th>
<th>Result</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colon (IBD, TNBS, and DSS colitis)</td>
<td>Human and mice</td>
<td>Colonic tissue</td>
<td>RT-qPCR</td>
<td>Upregulation TRPM8</td>
<td>93</td>
</tr>
<tr>
<td>Colon (TNBS and DSS colitis)</td>
<td>Mice</td>
<td>Colonic tissue</td>
<td>Immunohistochemistry</td>
<td>Increased TRPM8 expression</td>
<td>50</td>
</tr>
<tr>
<td>Colon (IBS)</td>
<td>Human</td>
<td></td>
<td>Symptom questionnaires</td>
<td>Treatment with TRPM8 agonist decreases IBS symptoms such as abdominal pain and increases quality of life</td>
<td>23, 24, 62, 76</td>
</tr>
<tr>
<td>Colon (TNBS and DSS colitis)</td>
<td>Mice</td>
<td>Serosal and mesenteric afferent nerves</td>
<td>Evaluation of pain-related behavior</td>
<td>Treatment with TRPM8 agonist increases visceral pain</td>
<td>50</td>
</tr>
<tr>
<td>Colon (TNBS and DSS colitis)</td>
<td>Mice</td>
<td>Colonic tissue and HEK-293 cells</td>
<td>Afferent nerve recording</td>
<td>TRPM8 activation desensitizes TRPV1 and TRPA1</td>
<td>48</td>
</tr>
<tr>
<td>Colon (TNBS postinflammatory VHS)</td>
<td>Rats</td>
<td>Colorectal distention</td>
<td>Calcium imaging</td>
<td>TRPM8 agonist has anti-inflammatory effect and inhibits capsaicin-induced responses</td>
<td>93</td>
</tr>
</tbody>
</table>

Mechanisms Underlying Sensitization of TRP Channels in Visceral Hypersensitivity

Given that TRP channels are crucial in the development and maintenance of VHS, it is clear that insight into the mechanisms contributing to persistent TRP channel activation or sensitization is key for the development of novel therapeutic strategies. In general, TRP channels play three distinct cellular roles: 1) TRP channels operate as molecular sensors, that is, primary detectors and transducers of chemical and physical stimuli from the microenvironment; 2) TRP channels act as downstream or secondary transducers of cell activation mediated by GPCRs or ion channel activation; and 3) TRP channels function as ion transport channels, for example, for Ca$^{2+}$ and Mg$^{2+}$ responsible for cellular homeostasis. Within primary afferent neurons, translation of signals detected by TRP channels into effector responses is carried out by the local release of neuropeptides from the peripheral fibers of TRP-expressing afferent neurons, which causes changes in local tissue function, and on the other hand, by transmission of the signals to the central nervous system resulting in (nociceptive) sensation.

Long-term deregulation and disease can lead to chronic TRP channel sensitization, thereby triggering VHS. However, the exact mechanisms underlying long-term sensitization of TRP channels in FGIDs are not fully understood. From somatic pain studies and studies in the skin we know that the GPCR-TRP axis plays a central role in TRP sensitization (114). Indeed, GPCRs enable sensory neurons to detect diverse stimulants and inhibitors, including amines (histamine and serotonin), peptides (kinins, tachykinins, and opioids), purines and nucleotides (adenosine and ATP), lipids (prostaglandins), steroids (bile acids), and proteases (serine and cysteine). The capacity of GPCRs to excite primary sensory neurons requires activation of TRP channels, and the activities of many GPCRs converge on a small number of TRP channels that are vitally important for sensory signaling. GPCRs can stimulate TRPs by two general mechanisms: 1) G$\alpha$-mediated activation of phospholipases that relieve phosphatidylinositol 4,5-bisphosphate (PIP2)-dependent channel inhibition and generate endogenous TRP agonists and 2) stimulation of kinases (protein kinase C, PKA, and tyrosine kinases) that phosphorylate TRPs to in-
TRPV1 contains numerous phosphorylation sites for serine and threonine protein kinases such as PKA, PKC, CaMK II, and sarcoma (Src) kinase, all of which regulate TRPV1 activity by a dynamic interplay between receptor phosphorylation and dephosphorylation (52). This complex system allows TRPV1 sensitization by various inflammatory mediators and receptors involved in TRP sensitization and VHS.

TRPV1. TRPV1 channels can amplify the effects of GPCRs and mediate their contributions to transmission of pain and neurogenic inflammation. Below we review the present knowledge of mediators and receptors involved in TRP sensitization and VHS.

### Table 6. GPCR signaling-mediated sensitization of TRP channels

<table>
<thead>
<tr>
<th>Receptor (Ligand)</th>
<th>Signaling Mechanism</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>TRPV1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BK2 (bradykinin)</td>
<td>PKC</td>
<td>107, 109</td>
</tr>
<tr>
<td>PAR-2 (protease)</td>
<td>PLC, PKC, PKA</td>
<td>30</td>
</tr>
<tr>
<td>Hrh1 (histamine)</td>
<td>PLC, PKC</td>
<td>58, 128</td>
</tr>
<tr>
<td>PGR (prostaglandin E2)</td>
<td>PKA</td>
<td>51, 95</td>
</tr>
<tr>
<td>TrkA (NGF)</td>
<td>PI3, Src kinase</td>
<td>55, 137</td>
</tr>
<tr>
<td>5HT1R, 5HT4R (serotonin)</td>
<td>PKA, PKC</td>
<td>106</td>
</tr>
<tr>
<td>TRPV4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PAR (protease)</td>
<td>PKA, PKC</td>
<td>43</td>
</tr>
<tr>
<td>Hrh1 (histamine)</td>
<td>PLC, PKC, PLA2, MAPK</td>
<td>11, 28</td>
</tr>
<tr>
<td>5HT1R (serotonin)</td>
<td>PKC, PLC, PLA2, MAPK</td>
<td>28</td>
</tr>
<tr>
<td>BK2 (bradykinin)</td>
<td>PLC</td>
<td>35</td>
</tr>
<tr>
<td>TRPA1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BK2 (bradykinin)</td>
<td>PLC, PKA</td>
<td>97, 120</td>
</tr>
<tr>
<td>PAR-2 (protease)</td>
<td>PKA, PKC, PLC, PIP2</td>
<td>30, 32</td>
</tr>
<tr>
<td>Hrh1 (histamine)</td>
<td>–</td>
<td>11</td>
</tr>
<tr>
<td>TRPM8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PGR (prostaglandin E2)</td>
<td>PKA</td>
<td>71</td>
</tr>
<tr>
<td>BK2 (bradykinin)</td>
<td>PKC</td>
<td>88</td>
</tr>
<tr>
<td>5HT1H (serotonin)</td>
<td>PIP2, PIP3</td>
<td>117</td>
</tr>
</tbody>
</table>

**GPCR, G protein-coupled receptor.**

GPCRs, G protein-coupled receptors, are potentiated in rectal submucosal neurons of IBS patients compared with those of healthy subjects (128), an effect that was histamine dependent. We showed an increased capsaicin-induced response of sensory DRG neurons after overnight incubation with rectal biopsy supernatants of IBS patients compared with healthy subjects. As this effect was also mediated via activation of the Hrh1 (128), we speculate that mediators released by immune cells, most likely mast cells, in the submucosa trigger TRP sensitization and neuronal hypersensitivity. A small pilot study in 55 IBS patients assessing the effect of the Hrh1 antagonist ebastine for 12 wk revealed that ebastine improved global symptom relief in ~46% of patients with the maximal effect from 8 wk onward (128).

TRPV4. TRPV4 is regulated by serine/threonine phosphorylation in a similar manner to TRPV1. Both PKC and PKA, as downstream molecules of GPCR activation by inflammatory mediators such as histamine, 5-HT, bradykinin, PGE2, and proteases, can enhance the activation of TRPV4 via phosphorylation at specific residues, and the phosphorylation depends on the assembly of PKC and PKA (35). Besides phosphorylation, incubation with histamine or serotonin triggered the translocation of TRPV4 to the membrane, an effect that can also contribute to neuronal potentiation (28).

As for TRPV1, the function of TRPV4 in visceral pain is strongly modulated by pro-inflammatory mediators that act on upstream GPCRs. For example, TRPV4 was found to be coexpressed with the protease receptor PAR-2 on nociceptive neurons (43, 100), and pretreatment of sensory DRG neurons with a PAR-2 agonist resulted in an enhanced TRPV4 activity, which was prevented by PKA and PKC inhibition (43). In vivo administration of subnociceptive doses of serotonin and histamine potentiated TRPV4-induced hypersensitivity in response to colorectal distention in mice, which was prevented by intravertebral injection of TRPV4 siRNA (28). Also, intraluminal administration of PAR-2 agonists resulted in an increased visceromotor response to colorectal distention, which was not observed in TRPV4 knockout mice (27, 100). In contrast, activation of PAR-4 significantly reduced the visceromotor response to colorectal distention in mice and inhibited PAR-2 agonist- and TRPV4 agonist-induced allodynia and hyperalgesia (10). These results are of particular interest as they demonstrate that activation of inhibitory GPCR receptor subunits can bind to inhibitory secondary signaling molecules, preventing and potentially reversing TRP potentiation.

TRPA1. Several studies on somatic pain already demonstrated that TRPA1 activation is also potentiated by GPCR activation. Indeed, both in vitro and in vivo experiments demonstrated that TRPA1 can be potentiated by bradykinin via PKA- and PLC-dependent pathways (97, 120). Also, activation
of PAR-2 by mast cell tryptase can trigger sensitization of TRPA1 involving PKA and PKC signaling, leading to somatic cold hyperalgesia in mice (30). In addition, TRPA1 sensitization by PAR-2 activation was observed in human embryonic kidney-293 (HEK-293) cells and DRG neurons, an effect that was mediated by PLC activation and phosphatidylinositol biphosphate (PIP2) (32). Degradation of PIP2 into diacylglycerol and inositol triphosphate leads to Ca2+ release from internal stores, and this intracellular Ca2+ mobilization may directly activate TRPA1 (139). Finally, inflammatory signals or acute activation of TRPA1 by mustard oil induces translocation of the TRPA1 channels to the membrane in sensory neurons which is PKA and PLC dependent (97).

In parallel, activation of colonic afferents with the inflammatory mediator bradykinin resulted in increased mechanosensitivity of these neurons, which was absent in TRPA1 knockout mice (19). Similarly, intracolonic administration of a PAR-2 agonist resulted in an increased visceromotor response to colorectal distention, which is abrogated by TRPA1 gene deletion (26). This finding was not confirmed by Brierley et al. (19), who did not find evidence to support an interaction of TRPA1 and PAR-2 in splanchnic colonic afferents. Although the role of TRPA1 sensitization seems well established in somatic pain, its role in VHS in FGIDs remains to be elucidated.

TRPM8. Unlike TRPV1, TRPV4, and TRPA1 whose activation is enhanced by phosphorylation, modulation of TRPM8 by protein kinases appears to function as a negative regulator. Although there are no data available on TRPM8 in VHS, somatic pain studies showed that PKC and PKA activation initiates dephosphorylation of TRPM8 via phosphatase activation (16, 88). Various studies in murine DRG neurons show that treatment with pro-inflammatory mediators bradykinin and PGE2 led to a reduction in the amplitude of the TRPM8 response to cooling, resulting in a shift of the threshold to colder values. These effects were mediated by PKC and PKA, respectively (16, 71, 88). Another report confirmed the involvement of PKC in TRPM8 desensitization in HEK-293 cells (2). Others showed that a subset of sensory neurons coexpress TRPM8 ion channels and 5-HT1B receptors (5-HT1BR). The 5-HT1BR has previously been reported to exert an antinoceptive influence (42, 60). 5-HT1BRs signal through PLD and PIP2 to potentiate TRPM8 activation, thereby amplifying TRPM8 attenuation of neuronal hypersensitivity (117). The authors also showed that 5-HT1BR activation led to the amplification of TRPM8-mediated analgesia in behavioral models of chronic pain (117).

On the other hand, there is recent evidence that the inflammatory mediators bradykinin and histamine can also inhibit TRPM8 activation independent of protein kinases via activation of the G protein subunit Go,q that binds TRPM8 and directly inhibits the ion channel activity (138). Thus inflammatory mediators not only enhance the activation of pronociceptive TRP channels (see above) but also desensitize TRPM8, resulting in even further enhanced inflammatory pain perception. Altogether, depending on the microenvironment and activated upstream GPCR, TRPM8 can exert both anti-and pronociception and may serve as an interesting target to treat VHS.

Cross Talk Between TRP Channels

As various TRP channels are coexpressed on sensory neurons and often simultaneously upregulated or sensitized potentially downstream of various activated GPCRs in preclinical and clinical VHS, it has been proposed that TRP channels may also cross-sensitize each other. Indeed, 97% of TRPA1-positive sensory neurons coexpress TRPV1, while 30% of the TRPV1-positive neurons also express TRPA1, suggesting that these two TRP channels can interact (104). Several studies indeed showed that activation of TRPA1 can modulate TRPV1 activity. For example, activation of TRPA1 in DRG neurons results in sensitization of TRPV1, which involves activation of adenyl cyclase, cyclic adenosine monophosphate (cAMP), and subsequent activation of PKA, leading to phosphorylation of TRPV1 (103). Furthermore, intraperitoneal injection of a TRPV1 antagonist combined with a TRPA1 antagonist in a mouse model of experimental colitis results in a significant decrease of VHS compared with injection of the antagonists separately, suggesting a synergistic effect (115). Another study shows desensitization of TRPA1 in sensory neurons due to PIP2 depletion by activation of TRPV1 by capsaicin (6). Furthermore, cannabinoid-induced TRPV1 dephosphorylation in sensory neurons is absent if TRPA1 is knocked down, suggesting interaction between TRPA1 and TRPV1 (54). Of interest, activation of TRPM8 resulted in a decrease of agonist-evoked responses to TRPA1 and TRPV1 in colonic afferents, suggesting coexpression and cross talk between TRPM8, TRPV1, and TRPA1 (48). Taken together, these data suggest that cross-(de)sensitization of TRP channels can contribute to pain sensitivity in inflamed tissues and may serve as novel therapeutic targets.

TRP Channels: Implications for Therapy

Mounting evidence indicates that TRP channels are attractive targets for novel analgesics effective in a wide range of pathophysiological conditions, including VHS among many others, and numerous companies have initiated research tracks to identify TRP modulators. However, antagonizing TRP channels is challenging as they are often not only expressed by visceral sensory neurons but also by a multitude of tissues, including higher brain structures, nonsensory neurons, and nonneuronal cells, leading to severe side effects. Recently, a number of small-molecule TRPV1 antagonists have been advanced into clinical trials. The systemic use of TRPV1 antagonists revealed two major drawbacks, namely hyperthermia and impaired noxious heat sensation, leading to their withdrawal from clinical trials (33, 39, 40, 90). Some TRPV1 antagonists patented in recent years overcame the known undesirable side effects, making the development of TRPV1 antagonists much more promising (67, 98). Besides TRPV1 antagonists, prolonged intake of capsaicin also appears to desensitize afferent nerves against noxious stimuli. For example, ingestion of capsaicin capsules by healthy volunteers three times per day for 4 wk have been shown to decrease the pain response evoked by duodenal capsaicin administration and balloon distention (37). In line with these results, treatment of FD patients with capsaicin capsules for 5 wk resulted in a significant reduction of visceral pain (18). The challenge for an effective and safe therapy, however, will be to rather suppress
the pathological contribution of TRPV1 to pain while preserving its physiological function.

TRPA1 may be a better candidate for therapeutic intervention as it is specifically expressed in a subclass of TRPV1-expressing nociceptors (104). TRPA1 antagonists do not have the same temperature regulation safety concerns as TRPV1 antagonists and may therefore be a more suitable target (89). Although the TRPA1 antagonist GRC17536 has shown efficacy in patients with painful diabetic neuropathy in Phase 2a proof-of-concept studies (89), studies on TRPA1 antagonism in VHS are completely lacking. To date there is also no clinical evidence available for TRPV4 antagonism, although new blockers have been developed and await to be assessed for their therapeutic efficacy and safety (116).

TRPM8 is often thought of as an ion channel giving rise to only nonpainful sensations, but more recent evidence suggests that TRPM8 channel agonists may have analgesic effects. Several double-blind placebo-controlled clinical trials indeed showed that ingestion of peppermint oil in IBS patients resulted in a significant decrease of abdominal pain perception while significantly improving quality of life in 75% of patients compared with 40% in patients treated with placebo (23, 62, 76). Moreover, a recent double-blind placebo-controlled clinical trial showed that ingestion of a novel formulation of peppermint oil with sustained release resulted in a 40% reduction of the total IBS symptom score (abdominal pain, bloating, urgency, etc.) after 4 wk treatment compared with 24.3% decrease in the placebo group (24). In addition herbal prepa-

---

**Fig. 1.** G protein-coupled receptor (GPCR) mediated transient receptor potential (TRP) channel sensitization contributing to visceral hypersensitivity. Activation of nociceptive Gs-linked receptors, such as bradykinin receptor (BK1), 5-hydroxytryptamine receptor (5HTR1), histamine receptor (Hrh2), and prostaglandin receptor (PGR), results in the production of cyclic adenosine monophosphate (cAMP) by adenylyl cyclase (AC). This leads to an increase of protein kinase C (PKC) activity resulting in TRP channel sensitization by phosphorylation. On the other hand, activation of nociceptive Gq-linked receptors, such as bradykinin receptor (BK2), protease-activated receptor 2 (PAR-2), 5-hydroxytryptamine receptor (5HTR2), histamine receptor (Hrh1), and prostaglandin receptor (PGR), leads to the production of diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) by phospholipase C (PLC), resulting in protein kinase A (PKA) activation, which leads to TRP channel phosphorylation and sensitization. In parallel, Goi activates phospholipase A2 (PLA2), leading to the production of arachidonic acid (AA) and downstream polyunsaturated fatty acids (PUFAs) that can directly activate TRP channels. Activation and sensitization by phosphorylation of TRP channels contribute to aberrant pain perception and visceral hypersensitivity (VHS). Activation of Goq-linked receptors by resolvins inhibits adenylyl cyclase, with subsequent downregulation of PKA antagonizing Gs-mediated sensitization. PIP2, phosphatidylinositol 4,5-bisphosphate; P, phosphate; Ca2+, calcium; Na+, natrium.
rations containing peppermint successfully relieve FD-related symptoms such as epigastric/abdominal pain, bloating, and heartburn in 78% of the treated patients (94).

Altogether, even though there are some preliminary positive reports, the direct blockade of TRP channels often leads to severe side effects. It has been suggested that indirect action on the modulation of these channels may be a more promising approach. As described above, inflammatory mediators lower the threshold of several pronociceptive TRPs via activation of the corresponding GPCR. Hence, VHS may be countered by interacting with this process. In this line of thinking, we recently showed that HRh1 antagonism prevents sensitization of TRPV1 on sensory neurons, resulting in significantly decreased abdominal pain in a proof-of-concept clinical trial (128). Since activation of PAR-2 has also been shown to sensitize TRPV1, TRPV4, and TRPA1 (30), blocking PAR-2 may also be a promising therapeutic approach; however, so far clinical evidence is lacking. Stimulation of GPCRs results in activation of several protein kinases that phosphorylate and sensitize TRP channels. Inhibition of the downstream pathways of GPCRs activation may represent an interesting alternative therapeutic approach for VHS. The success of kinase inhibitors in the treatment of cancer showcased their therapeutic potential (136). This success, coupled with a greater understanding of inflammatory signaling cascades, led to kinase inhibitors taking center stage in the pursuit for new anti-inflammatory agents for the treatment of (auto)-immune-mediated diseases (70). To date only a handful of kinase inhibitors have reached the stage of FDA approval, while others have had mixed results in clinical trials. It remains to be determined if protein kinases are good drug targets to treat FGIDs.

Recently, somatic pain studies have indicated that resolvins (Rv), a new class of compounds known for their anti-inflammatory properties, prevent activation of TRP channels including TRPA1, TRPV1, and TRPV4 (1, 13, 82, 132). Resolvins are endogenous lipid mediators produced by immune cells, including eosinophils and neutrophils, and drive the resolution phase of inflammation even at concentrations in the nanomolar range (99). Understandably, evidence is quickly growing for their pain-relieving potential too. To date, especially, RvE1, RvD1, and RvD2 have been studied for their analgesic properties. Increasing evidence shows that these resolvins potently interfere with TRP channel function, independent of their effect on the immune system (99). RvE1 and RvD1 were shown to normalize inflammatory pain by central and peripheral actions (132). Furthermore, resolvins inhibited acute pain evoked by intraplantar injection of TRPV1, TRPV4, and TRPA1 agonists. Also, in vitro, in DRG neurons and HEK cells, TRPV1, TRPV4, and TRPA1 signaling could be inhibited by RvD1, RvD2, and RvE1 (13, 82, 132). Besides TRP channel activation, it can be speculated that resolvins also prevent TRP channel sensitization. The mechanism by which resolvins inhibit TRP channel activation and sensitization is not entirely unraveled. It is proposed that resolvins activate inhibitory GPCR (Gαi) that antagonize the GPCR-mediated sensitization of TRP channels. Activation leads to inhibition of adenyl cyclase-dependent cAMP production and subsequent downregulation of PKA-mediated TRP sensitization (126). Therefore, this signaling mechanism is potentially a very interesting approach for resolving VHS in FGIDs, mediated by TRP channel sensitization.

Conclusions

Relief of chronic pain in FGIDs, including FD, IBS, and IBD in remission, is a largely unmet medical need. This review underscores the critical role of TRP ion channels in peripheral neuronal sensitization, generating and sustaining chronic pain by the increase in neuronal excitability in primary sensory neurons. TRP channels not only function as detectors of thermal, chemical, and mechanical stimuli but also serve as secondary transducers in which activation of various GPCRs by pro-inflammatory mediators triggers TRP sensitization leading to aberrant pain perception (Fig. 1). Therefore, TRP channels as well as the GPCRs and downstream signaling molecules are promising drug targets for the management of VHS as seen in several FGIDs. Since multiple inflammatory mediators have been identified that can individually result in TRP channel modulation via GPCR signaling, identifying the mediator signature in individual patients with VHS is key to predicting which treatment would be beneficial for relieving symptoms.

GRANTS

G. Boecxkstaens was funded by a governmental grant (Odysseus program, G-090507) of the Research Foundation-Flanders (FWO) and by a KU Leuven university grant (Global Opportunities for Associations GOA 14.011). M. Wouters was supported by a FWO postdoctoral fellowship (1248513N and 12C2113N, respectively). D. Balemans was supported by a FWO PhD fellowship (1127415N). This work was funded by FWO research grant G069910N (to G. Boecxkstaens and M. Wouters). K. Talavera was funded by a KU Leuven university grant (PF-TRPLe).

DISCLOSURES

No conflicts of interest, financial or otherwise, are declared by the author(s).

AUTHOR CONTRIBUTIONS

D.B. prepared figures; D.B. drafted manuscript; D.B., G.E.B., K.T., and M.M.W. edited and revised manuscript; D.B., G.E.B., K.T., and M.M.W. approved final version of manuscript.

REFERENCES

TRP CHANNELS IN VISCERAL HYPERSENSITIVITY

G645


23. Gonlachanvit S, Mahayosnond A, Kullavanijaya P. Effects of chili on postprandial gastrointestinal symptoms in diarrhoea predominant irrita-
TRP CHANNELS IN VISCERAL HYPERSENSITIVITY


Güler 44.
Hosoya 50.
Holzer 49.
Jones 56.
Hwang 53.
Halpin 45.
Gordillo-González 42.
Grant 48.
Harrington 57.

Holmer 57.

Högestätt ED, Meng ID, Julius D. 1111/j.1442-2050.2010.01124.x.

Jones 56.
Holzer 49.
Hargreaves KM. 1111/j.1365-2982.2000.01167.x.

Jones 56.


TRP CHANNELS IN VISCERAL HYPERSENSITIVITY


Downloaded from http://ajpgi.physiology.org/ by 10.220.32.247 on June 30, 2017


124. Wehrhahn J, Kraft R, Harteneck C, Hauschild T, Szent Novak A. Transient receptor potential melastatin 2 is required for lipopolysaccharide-induced cyto-